Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V3-MOMMO in breast cancer
NCT03572361Phase 2Unknown
- Sponsor
- Immunitor Inc.
- Start
- Jul 2018
- Primary completion
- Nov 2019
- Modality
- Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of V3-MOMMO in breast cancer, sponsored by Immunitor Inc. Primary endpoint: Effect on tumor size at 3 months. Status: unknown.
02
Drugs
V3-MOMMO
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03572361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03572361.